Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TAK
TAK
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TAK News
Spyre Therapeutics' Trial Data Boosts Stock by 23%
Apr 13 2026
stocktwits
Takeda Ends Collaboration Agreement with Denali Therapeutics on DNL593
Apr 03 2026
moomoo
Biotech Landscape Update: Regulatory Approvals and Acquisitions
Apr 03 2026
NASDAQ.COM
Axsome Acquires Global Rights to TAK-063 from Takeda
Apr 01 2026
NASDAQ.COM
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion
Mar 31 2026
Newsfilter
Eli Lilly to Acquire Centessa Pharmaceuticals for Up to $7.8 Billion
Mar 31 2026
CNBC
Takeda Reports Promising Phase 3 Data for Zasocitinib in Psoriasis
Mar 29 2026
NASDAQ.COM
Zasocitinib Shows Significant Efficacy in Psoriasis Studies
Mar 28 2026
Newsfilter
Zasocitinib Shows Significant Efficacy in Psoriasis Studies
Mar 28 2026
Yahoo Finance
Takeda Plans Over ¥200B in Annual Savings by 2028
Mar 25 2026
seekingalpha
Weave Bio Forms Strategic Advisory Board to Enhance AI in Regulatory Processes
Mar 25 2026
Yahoo Finance
Abivax Plans Fundraising Following Key Trial Data Release
Mar 24 2026
CNBC
Takeda Pharmaceutical Plans 400 Layoffs to Boost Profitability
Mar 04 2026
seekingalpha
Rusfertide Shows Significant Improvements in Patient Outcomes for Polycythemia Vera in Pivotal Study
Mar 02 2026
Newsfilter
Keros Therapeutics Initiates DMD Trial and Plans ALS Phase II Discussions
Feb 28 2026
Yahoo Finance
Mental Health Treatment Market Set for Accelerated Growth
Feb 24 2026
PRnewswire
Show More News
